Stereoselective analysis of labetalol in human plasma by LC-MS/MS: Application to pharmacokinetics

Chirality

Volumn 21, Issue 8, 2009, Pages 738-744

  Carvalho, Teresa Maria de Jesus Ponte ^a   Cavalli, Ricardo de Carvalho ^a   Marques, Maria Paula ^a   da Cunha, Sérgio Pereira ^a   Baraldi, Claúdia de Oliveira ^a   Lanchote, Vera Lúcia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Enantiomers; Hypertension; Labetalol; LC MS MS; Pharmacokinetics; Pregnancy

Indexed keywords

LABETALOL;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CASE REPORT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; FIRST PASS EFFECT; HUMAN; HYPERTENSION; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEREOCHEMISTRY; STEREOISOMERISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIHYPERTENSIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; LABETALOL; MOLECULAR STRUCTURE; PHARMACOKINETICS; PREGNANCY; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

EID: 70349536044     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20673     Document Type: Article

References (23)

1. Elatrous S, Nouira S, Besbes O, Marghli S, Boussarssar M, Sakkouhi M, Abroug F. Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. Intensive Care Med 2002;28:1281-1286.
2. Donelly R, Macphee GI. Clinical pharmacokinetics and kinetics-dynamic relationships of dilevalol and labetalol. Clin Pharmacokinet 1991;21:95-109.
3. Johnson JA, Akers WS, Herring VL, Wolfe MS. Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. Pharmacotherapy 2000;20:622-628.
4. Dakers JM, Boulton DW, Fawcett JP. Sensitive chiral high-performance liquid chromatographic assay for labetalol in biological fluids. J Chromatogr B 1997;704:215-230.
5. Goel TV, Nikelly JG, Simpson RC, Mattuszewski BK. Chiral separation of labetalol stereoisomers in human plasma by capillary eletrophoresis. J Chromatogr A 2004;1027:213-221.
6. Lalonde RL, O'Rear TL, Wainer JW, Drda KD, Herring VL. Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. Clin Pharmacol Ther 1990;48:509-519.
7. Niemeijer NR, Gerding TK, Zeeuw RA. Glucuronidation of labetalol at labetalol at the two hydroxy positions by bovine liver microsomes. Drug Metabol Dispos 1991;19:20-23.
8. Martin LE, Hopkins R, Bland R. Metabolism of labetalol by animals and man. Br J Clin Pharmacol 1976;3(4 Suppl 3):695-710.
9. Martin LE, Carey P, Bland R. Assay of labetalol and its metabolites in biological fluids. Meth Surveys Biochem 1978;7:227-242.
10. Yeleswaram K, Rurak DW, Kwan E, Hall C, Doroudian A, Abbott FS, Axelson JE. Disposition, metabolism and pharmacodynamics of labetalol in adult sheep. Drug Metabol Dispos 1993;2:284-292.
11. Alton KB, Chan T, Pramanik BN. Urinary metabolites of (R),(R)- labetalol. Drug Metabol Dispos 1994;22:866-872.
12. Gal J, Zirrolli JA, Lichtenstein PS. Labetalol is metabolized oxidatively in humans. Res Commun Chem Pathol Pharmacol 1988;62: 3-17.
13. Yeleswaram K, Rurak DW, Kwan E, Hall C, Abbott FS, Axelson JE. Identification and quantification of an oxidative metabolite of labetalol in sheep: pharmacokinetic and metabolic implications. Biol Mass Spectrom 1992;21:534-540.
14. Bazylak G, Aboul-Enein HY. Direct separation of labetalol stereoisomers in a high performance liquid chromatography system using helically self-assembed chelate as chiral selector in the mobile phase. J Liq Chromatogr Relat Technol 1999;22:1171-1192.
15. Desai DM, Gal J. Reversed-phase high-performance liquid chromatographic separation of the stereoisomers of labetalol via derivation with chiral and non-chiral isothiocyanate reagents. J Chromatogr 1992;579: 165-171.
16. 1-acid glycoprotein stationary phase. J Chromatogr 1993;619:79-86.
17. Umezawa H, Lee X, Arima Y, Hasegawa C, Izawa H, Kumazawa T. Simultaneous determination of β-blockers in human plasma using liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2008;22:702-711.
18. Andrisano V, Ballardini R, Hrelia P, Cameli N, Tosti A, Gotti R, Cavrini V. Studies on the photostability and in vitro phototoxicity of labetalol. Eur J Pharmacol Sci 2001;12:495-504.
19. Yeleswaram K. Sensitive microbore high-performance liquid chromatographic assay for labetalol in the biological fluids of pregnant sheep. J Chromatogr 1991;565:383-390.
20. Alton KB, Leitz F, Bariletto S, Jaworsky L, Desrivieres D, Patrick J. High-performance liquid chromatographic assay for labetalol in human plasma using a PRP-1 column and fluorimetric detection. J Chromatogr 1984;311:319-328.
21. Rubin PC, Butters L, Kelman A, Kitzsimons C, Reid JL. Labetalol disposition and concentration-effect relationships during pregnancy. Br J Clin Pharmacol 1983;15:465-470.
22. Rogers RC, Sibai BM, WhybrewWD. Labetalol pharmacokinetics in pregnancy-induced hypertension. Am J Obstet Gynecol 1990;162:362-366.
23. Saotome T, Minoura S, Tersahi K, Sato T, Echizen H, Ishizaki T. Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. J Clin Pharmacol 1993;33:979-988.